Similar studies for GEO DataSets (Select 3829) - GEO DataSets

Warning: The NCBI web site requires JavaScript to function. more...

Links from GEO DataSets

Items: 12

Select item 38291.

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy effect on chronic lymphocytic leukemia

Analysis of CD19+ selected B cells from CLL patients before and after chemoimmunotherapy regimens of rituximab (R), fludarabine and cyclophosphamide (FC), or RFC. Results provide insight into the molecular mechanisms underlying the beneficial effects of the chemoimmunotherapy regimens.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 5 agent sets

Platform:: GPL570
Series:: GSE15490
50 Samples

Download data: CEL

DataSet

Accession:: GDS3829

ID:: 3829

Select item 2000154902.

Sequential gene expression profiling in CLL during treatment

(Submitter supplied) Purpose: Accurate prediction of clinical response is the prerequisite for individualized therapy in chronic lymphocytic leukemia (CLL). We hypothesized that sequential assessment of gene expression changes early during therapy may well reflect behaviour of the leukemic clone in response to specific drugs. Patients and Methods: Gene expression profiles (GEP) were determined in CD19+ selected B-cells from 20 patients treated with fludarabine and cyclophosphamide (FC) (N=10) or FC plus rituximab (FCR) (N=10). more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS3829
Platform:: GPL570
50 Samples

Download data: CEL

Series

Accession:: GSE15490

ID:: 200015490

Select item 2000278583.

The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia

(Submitter supplied) SPC2996 is a novel locked nucleic acid (LNA) phosphorothioate antisense molecule targeting the mRNA of the Bcl-2 oncoprotein. We investigated the mechanism of action of SPC2996 and the basis for its clinically observed immunostimulatory effects in chronic lymphocytic leukemia (CLL). Patients with relapsed CLL were treated with a maximum of six doses of SPC2996 (0.2-6mg/ kg) in a multicenter phase I trial. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS4284
Platform:: GPL570
56 Samples

Download data: CEL, CHP

Series

Accession:: GSE27858

ID:: 200027858

Select item 42844.

Chronic lymphocytic leukemia response to antisense Bcl-2 inhibitor SPC2996: peripheral blood

Temporal analysis of peripheral blood from 18 relapsed CLL patients treated with a maximum of 6 doses (0.2-6mg/kg) of SPC2996, an antisense molecule targeting the mRNA of Bcl-2 oncoprotein. Results provide insight into the molecular basis of the immunostimulatory effects of SPC2996 in CLL.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 6 dose, 18 individual, 4 time sets

Platform:: GPL570
Series:: GSE27858
56 Samples

Download data: CEL, CHP

DataSet

Accession:: GDS4284

ID:: 4284

Select item 2000024035.

Stable and Progressive B-CLL

(Submitter supplied) Objective. B-cell chronic lymphocytic leukemia is a heterogeneous disease with a pronounced variation in the clinical course. With the purpose of identifying genes that could be related to disease progression, we have performed gene expression profiling on B-CLL patients with an indolent disease and patients with a progressive disease with need for therapy. Materials and Methods. We applied the Affymetrix GeneChip technique to 11 B-CLL patients with stable and 10 patients with clinically progressive disease. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS1388
Platform:: GPL8300
21 Samples

Download data

Series

Accession:: GSE2403

ID:: 200002403

Select item 13886.

B-cell chronic lymphocytic leukemia progression

Analysis of primary lymphocytes from B-cell chronic lymphocytic leukemia (B-CLL) patients. Lymphocytes from patients with indolent B-CLL compared to those with progressive B-CLL. Results identify putative gene markers of B-CLL progression from a stable to an aggressive state.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 2 disease state sets

Platform:: GPL8300
Series:: GSE2403
21 Samples

Download data

DataSet

Accession:: GDS1388

ID:: 1388

Select item 2000227627.

An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia

(Submitter supplied) Chronic lymphocytic leukemia (CLL) is a common and heterogeneous disease. An accurate prediction of outcome is highly relevant for the development of personalized treatment strategies. Microarray technology was shown to be a useful tool for the development of prognostic gene expression scores. However, there are no gene expression scores which are able to predict overall survival in CLL based on the expression of few genes that are better than established prognostic markers. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platforms:: GPL570 GPL96 GPL97
195 Samples

Download data: CEL

Series

Accession:: GSE22762

ID:: 200022762

Select item 2000159138.

Thalidomide Exerts Distinct Molecular Antileukemic Effects

(Submitter supplied) Thalidomide Exerts Distinct Molecular Antileukemic Effects and Combined Thalidomide/Fludarabine Therapy is Clinically Effective in High-Risk Chronic Lymphocytic Leukemia Background: Thalidomide represents a promising immunomodulatory drug that targets both leukemia cells and the tumor microenvironment. Methods: We treated chronic lymphocytic leukemia (CLL) patients with a combined thalidomide/fludarabine regimen and monitored cellular and molecular changes induced by thalidomide in-vivo prior to fludarabine treatment. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Platform:: GPL570
40 Samples

Download data: CEL, CHP

Series

Accession:: GSE15913

ID:: 200015913

Select item 2000063219.

Analysis of CD38+ and CD38- sub-clones derived from the same CLL patient

(Submitter supplied) CD38 expression is an important prognostic marker in CLL with high levels of CD38 associated with shorter overall survival. In this study, we used gene expression profiling and protein analysis of highly purified cell-sorted CD38+ and CD38- chronic lymphocytic leukemia cells to elucidate a molecular basis for the association between CD38 expression and inferior clinical outcome. Paired CD38+ and CD38- CLL cells derived from the same patient were shown to be monoclonal by VH gene sequencing but despite this, CD38+ CLL cells possessed a distinct gene expression profile when compared with their CD38- sub-clones. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS2676
Platform:: GPL571
12 Samples

Download data: CEL

Series

Accession:: GSE6321

ID:: 200006321

Select item 267610.

CD38-positive and CD38-negative chronic lymphocytic leukemia cells

Analysis of paired CD38(+) and CD38(-) chronic lymphocytic leukemia (CLL) cells from six patients. CD38 expression is an important prognostic marker in CLL with high levels of CD38 antigen associated with shorter overall survival. Results provide insight into the molecular basis of this association.

Organism:: Homo sapiens

Type:: Expression profiling by array, count, 2 cell type, 6 individual sets

Platform:: GPL571
Series:: GSE6321
12 Samples

Download data: CEL

DataSet

Accession:: GDS2676

ID:: 2676

Select item 20000439211.

Expression data from native ZAP-70+CD38+ vs. ZAP-70-CD38- CLL cells

(Submitter supplied) B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly variable clinical course and analysis of ZAP-70 and CD38 expression on B-CLL cells allowed for identification of patients with good (ZAP-70-CD38-), intermediate (discordant expression of ZAP-70 and CD38) and poor (ZAP-70+CD38+) prognosis. In an attempt to identify a molecular basis that may underly this diverse clinical behaviour DNA microarray technology was employed to compare eight ZAP-70+CD38+ with eight ZAP-70-CD38- B-CLL cases. more...

Organism:: Homo sapiens

Type:: Expression profiling by array

Dataset:: GDS2501
Platform:: GPL96
16 Samples

Download data

Series

Accession:: GSE4392

ID:: 200004392

Select item 250112.

B-cell chronic lymphocytic leukemia cell type and prognosis

Analysis of B-cell chronic lymphocytic leukemia (B-CLL) cells that express or do not express zeta-associated protein (ZAP-70) and CD38. The prognosis of patients with ZAP-70-CD38- B-CLL cells is good, those with ZAP-70+CD38+ B-CLL cells is poor.